Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer
Condition: HER2-positive Breast Cancer Interventions: Drug: Pyrotinib; Drug: Placebo Oral Tablet; Drug: Trastuzumab; Drug: Docetaxel Sponsor: Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | Docetaxel | HER2 | Herceptin | Neoadjuvant Therapy | Research | Study | Taxotere